Abstract
Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal MYCN expression is one of the strongest predictors of poor prognosis. It is present at diagnosis and is never acquired during later tumorigenesis of MYCN non-amplified neuroblastoma. This suggests that increased MYCN expression is an early event in these cancers leading to a peculiar dysregulation of cells that results in embryonal or cancer stem-like qualities, such as increased self-renewal, apoptotic resistance, and metabolic flexibility.
Author supplied keywords
Cite
CITATION STYLE
Otte, J., Dyberg, C., Pepich, A., & Johnsen, J. I. (2021, January 27). MYCN Function in Neuroblastoma Development. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2020.624079
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.